A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neutropenia
Interventions: BIOLOGICAL: F-627|BIOLOGICAL: Filgrastim
Sponsor: EVIVE Biotechnology
Collaborators: Fudan University|Affiliated Cancer Hospital & Institute of Guangzhou Medical University|Nanfang Hospital, Southern Medical University|The Affiliated Hospital of Qingdao University|Tongji Hospital|The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China|RenJi Hospital|Zhejiang Cancer Hospital|Yunnan Cancer Hospital|Henan Cancer Hospital|Jiangsu Provincial People's Hospital|Huaxi Hospital